Compare STMicroelectronics NV (STM) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
STMicroelectronics NV vs Travere Therapeutics Inc. Common Stock — how do they compare? STMicroelectronics NV trades at $45.08 (market cap $43.80B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: STMicroelectronics NV is far larger — about 9× Travere Therapeutics Inc. Common Stock's market cap, and STMicroelectronics NV pays a 0.73% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold STMicroelectronics NV for 65 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| STM | TVTX | |
|---|---|---|
Market Cap | $43.80B | $4.88B |
Volume | 7,353,071 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $79.91 | $67.52 |
52-Week Low | $21.20 | $26.79 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | $41.32B | $5.01B |
Dividend Yield | 0.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
STM is trading at $46.9, down 7.09% in the last session, with a bearish technical signal. The company shows mixed fundamentals with a high P/E ratio of 94.59 but negative net income margin of -0.39%. Recent Q2 2026 earnings beat expectations with EPS of $0.31 versus $0.26 expected, while Q1 and Q4 2025 missed. Strong cash flow of $555M in 2025 and improving 2026 projections provide some optimism amid current weakness.
The outlook remains cautious with analyst consensus price target of $77.31 suggesting 65% upside potential. Key opportunities include AI data-center revenue projected to exceed $2B in 2027 and automotive sensor innovations. Risks include declining revenue trends from $17.3B in 2023 to $11.8B in 2025 and negative profitability metrics requiring careful monitoring.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
